Background The role of peripheral tumor necrosis factor alpha (TNFα) in inflammatory bowel disease (IBD) is well established, but its central nervous system (CNS) effects are not understood. Thrombin, another mediator of inflammation in IBD, has been implicated in CNS vagal neuron apoptosis in the dorsal motor nucleus of the vagus (DMV). This study evaluates DMV TNFα exposure, characterizes effects of TNFα on DMV neurons, and identifies a relationship between DMV TNFα and thrombin in IBD. Methods 2,4,6-Trinitrobenzene sulfonic acid was administered via enema to induce colonic inflammation in rats. TNFα in serum, cerebrospinal fluid (CSF), and DMV tissues were determined by ELISA and DMV TNFα expression by quantitative reverse transcription PCR (RT-PCR). TNFα was administered into the fourth intracerebral ventricle (4 V) adjacent to the DMV, with and without blockade of TNF receptor 1 (TNFR1) and the thrombin receptor proteinase-activated receptor 1 (PAR1). Immunofluorescence was used to evaluate microglial activation (Cd11b) and prothrombin presence in DMV sections. Apoptosis was examined using terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) and activated caspase-3 immunofluorescence. Results IBD is associated with increased TNFα protein in serum, CSF, and DMV tissue; DMV TNFα transcription is also increased. TNFα (4 V) caused a 54 % increase in microglial activation, a 27 % increase in DMV prothrombin protein, and a 31 % increase in vagal neuron apoptosis by TUNEL. There was a 52 % increase in activated caspase-3 immunofluorescence in TNFα-treated animals (p<0.05). All effects of 4 V TNFα were prevented by TNFR1 blockade. TNFα-induced apoptosis was prevented by PAR1 blockade. Conclusions IBD is associated with DMV exposure to TNFα, causing excess DMV prothrombin and vagal apoptosis.
increased TNFα expression in inflamed intestinal mucosa. 1 TNFα traverses the blood-brain barrier and is produced locally within the brain. 2, 3 CNS neurons and glia express TNF receptor 1 (TNFR1) and are known to be affected by TNFα in other states of neuroinflammation. [3] [4] [5] [6] The following studies link TNFα to DMV thrombin exposure and establish a role for TNFα in the vagal neuronal apoptosis associated with IBD.
Materials and Methods

Chemicals and Solutions
Neurobasal A medium, B27 supplement, penicillin/ streptomycin, L-glutamine, trypsin type I, fibroblast growth factor, fura-2-AM, TRIzol reagent, goat serum, and ProLong Antifade with 4′,6-diamidino-2-phenylindole (DAPI) were purchased from Life Technologies, formerly Invitrogen (Carlsbad, CA). Recombinant DNase I and the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) in situ cell death detection kit, TMR red, were obtained from Roche Diagnostics (Indianapolis, IN). Triton X-100 and recombinant rat TNFα were obtained from Thermo Fischer (Waltham, MA). The small molecule proteinase-activated receptor 1 (PAR1) inhibitor FR171113 was purchased from Tocris Bioscience (Ellisville, MO). TNFα ELISA was accomplished using a rat TNFα DuoSet ELISA kit and reagents from R&D Systems (Minneapolis, MN). 5-Thio-D-glucose was purchased from M P B i o m e d i c a l s , L L C ( S o l o n , O H ) . 2 , 4 , 6 -Trinitrobenzenesulfonic acid (TNBS) and the small molecule TNFα inhibitor, SPD304, were obtained from Sigma-Aldrich (St. Louis, MO). Primary antibodies used in these studies include mouse anti-Hu from Invitrogen (Carlsbad, CA), mouse anti-Cd11b and clone OX-42 from AbD Serotec (Raleigh, NC), and rabbit anti-prothrombin from Abbiotec, LLC (San Diego, CA). Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG and tetramethyl rhodamine iso-thiocyanate (TRITC)-conjugated goat anti-rabbit IgG obtained from Jackson ImmunoResearch (West Grove, PA) were used as secondary antibodies. Intracerebroventrical cannulas were purchased from Plastics One (Roanoke, VA) and cut to 7.4 mm.
Animal Care
All animal studies were approved by the University of Michigan Committee on the Use and Care of Animals. Animals were housed in a temperature-controlled environment with 12-h light and dark cycles and access to food and water ad libitum.
IBD Model
Male Sprague-Dawley rats weighing 220-250 g were briefly anesthetized with isoflurane. To induce intestinal inflammation, a 0.5-ml enema containing 30 mg of TNBS in 50 % ethanol was administered. Control animals received a 0.5-ml enema of 0.9 % saline. Weight and food intake were monitored daily; animals were sacrificed humanely on posttreatment day 4. Rats were first deeply anesthetized. Where indicated, whole blood was collected from the orbital sinus and allowed to clot. It was then centrifuged at 4°C for 20 min at approximately 1,500g, and the serum was preserved at −80°C until use. Cerebrospinal fluid (CSF) was collected from the cisterna magna as previously described 7 and then stored at −80°C. For all other cases, rats were deeply anesthetized prior to intracardiac perfusion with phosphate-buffered saline (PBS). For collection of fresh DMV tissue, anesthetized rats were decapitated, and their brains were removed and quickly frozen and then stored at −80°C until use. Those animals whose brains were intended for immunofluorescence were also perfused with 4 % paraformaldehyde. Brains were subsequently removed, post-fixed in 4 % paraformaldehyde overnight, transferred to 20 % sucrose in PBS for 5 days, and finally embedded in 20 % sucrose and OCT. Tissue blocks were sectioned in 10-μm slices through the DMV using a cryostat. Sections were mounted such that each slide contained samples from each treatment group.
Quantitating TNFα ELISA for rat TNFα was performed according to the manufacturer's instructions, with all samples run in duplicate. Samples included rat serum and CSF collected as described above as well as protein extract from DMV tissue. Rat brains stored at 80°C were transferred to dry ice and placed into a metal form (Braintree Scientific, Braintree, MA) where 1-mm sections of medulla were created. The DMV was identified directly ventral to the nucleus of the solitary tract and dorsal to the hypoglossal nucleus. This area was excised with a tissue punch and total protein extracted using Triton X-100.
TNFα production in rat DMV tissue was also evaluated with quantitative real-time PCR (RT-PCR). DMV tissue samples obtained as for protein extraction were instead homogenized in TRIzol reagent, and total RNA was isolated by phase separation and precipitation. RNA was then converted to cDNA with reverse transcriptase. PCR primers and probe were developed using published sequences for the rat TNFα gene: forward: 5′ -CTT CTC ATT CCT GCT CGT GG -3′, reverse: 5′ -TGA TCT GAG TGT GAG GGT CTG -3′, and probe: 5′ -/56-FAM/AAC TTC TCC/ZEN/TCC TTG TTG GGG ACC G/31ABkFQ/ -3′. Real-time quantitative PCR was performed in triplicate for each sample, and messenger RNA (mRNA) was quantified using the comparative cross threshold (CT) method. Values were normalized to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Reaction products were also visualized by agarose gel electrophoresis.
The Fourth Ventricle Cannula
Male Sprague-Dawley rats weighing 270-310 g were anesthetized with intraperitoneal ketamine and xylazine. A 26-G single lumen cannula was introduced into the fourth intracerebral ventricle stereotactically according to coordinates published by Paxinos and Watson: midline, 13 mm caudal to bregma, and 7.4 mm deep with a head tilt of 0-3.3 mm. 8 The cannula was secured with craniofacial cement. A sterile internal cannula was placed to maintain patency and to prevent infection. On post-procedure day 3, cannula position was tested by fourth intracerebroventricular (ICV) injection of 5-thio-D-glucose, 210 μg in 3 μl PBS. A greater than 50 % rise in blood glucose in response to 5-thio-D-glucose was considered to be a confirmation of correct cannula position. On postprocedure day 7, animals underwent 4 μl injection of either artificial CSF, TNFα (700 pg), TNFα (700 pg=10 −8 M monomer) and SPD304 (2.5 μg=10 −4 M), or TNFα (700 pg) plus FR171113 (1.9 ng=10 −6 M). The second dose was administered 20 h later. Rats were deeply anesthetized and sacrificed 24 h after the initial dose. Intracardiac perfusion, preparation of tissue blocks, and sectioning were performed as described above. The TNFα dose chosen was just above the threshold dose demonstrated to delay gastric transit when administered directly into the DVC, accounting for distribution within the CSF volume. 9 SPD304 and FR171113 doses were chosen to exceed the IC 50 based on dose-inhibition studies.
10,11
Immunofluorescence Slides were first washed in PBS for 30 min and then were incubated with a blocking solution (10 % normal goat serum, 3 % bovine serum albumin (BSA), and 0.2 % Triton X-100 in PBS, pH 7.4) for 1 h at room temperature. Sections were then treated with primary antibody at 4°C for 48 h, washed in PBS, and treated with secondary antibody for 1 h at room temperature. Finally, slides were incubated with DAPI (1:5,000) and mounted with ProLong Gold Antifade reagent. All antibodies were diluted with a blocking solution. Primary antibodies utilized include mouse anti-Hu (1:100), mouse anti-Cd11b (1:100), and rabbit anti-prothrombin (1:50). TRITCconjugated goat anti-rabbit IgG (1:100) and FITCconjugated goat anti-mouse IgG (1:100) were used as secondary antibodies. Slides were viewed using a fluorescent microscope (Nikon Eclipse Ti-U). The DMV was identified as described above. Immunofluorescence was calculated using ImageJ software; background immunofluorescence was subtracted from the mean immunofluorescence within the DMV to yield an estimation of the excess immunofluorescence per unit of area attributable to the antibody in question. This process was performed for both the right and left DMV in each section.
TUNEL Assay
Apoptosis of DMV neurons was determined by TUNEL assay. Rat brain sections prepared as described above were treated for 5 min with a permeabilizing solution containing 0.1 % Triton X-100 and 0.1 % sodium citrate in PBS. Permeabilized sections were incubated with TUNEL reaction mixture in the dark, humidified chamber at 37°C for 1 h and then were rinsed in PBS. Negative controls were incubated with a labeling solution devoid of terminal transferase; positive controls were treated with recombinant DNase I (300 U/ ml DNase I and 1 % BSA in 50 mM Tris-HCl, pH 7.5) for 10 min at room temperature prior to the TUNEL reaction. Slides were then co-stained with mouse anti-Hu (1:100), FITC-conjugated goat anti-mouse IgG (1:100), and DAPI as described above. TUNEL positivity was quantified using ImageJ software as described above.
Statistical Methods
Data were analyzed with GraphPad Prism® software from GraphPad Software, Inc. (San Diego, CA), using ANOVA and paired or unpaired Student's t tests as appropriate. Bonferroni test was applied in cases of multiple comparisons. Results are expressed as mean±SEM. Significance was accepted at p<0.05.
Results
IBD and Elevated TNFα Concentrations in Serum, CSF, and DMV Tissue Extract
To confirm elevated circulating TNFα in rats with TNBS colitis, we evaluated serum TNFα concentration by ELISA both before and after induction of colitis. Prior to the administration of saline (control) or TNBS (colitis) enemas, control and colitis groups had similarly low levels of serum TNFα as detected by ELISA (1.6±1.4 vs. 2.0±1.4 pg/ml, n=10). After the induction of colitis, the TNBS group exhibited a nearly fivefold elevation in serum TNFα as compared to the baseline levels (9.8±7.4 vs. 2.0±1.4 pg/ml, n=10, Fig. 1a) , whereas serum TNFα concentration in the control group did not differ from baseline (1.0±0.7 vs. 1.6±1.4 pg/ml, n=10).
CSF concentrations of TNFα were four times higher in the TNBS group (3.6±1.6 vs. 0.8±0.6 pg/ml, n=9, Fig. 1b) . Examination of DMV tissue protein extract also revealed higher concentrations of TNFα protein in the colitis group (4.9 vs. 2.0 pg TNFα/μg total protein, n=9, Fig. 1c ). To determine whether the elevated TNFα protein levels might be related to increased local expression, we evaluated TNFα mRNA by quantitative RT-PCR in DMV tissue samples. There was a greater than 15-fold elevation in DMV TNFα transcripts in those animals with colitis (15.7±9.6 vs. 1.0±0.5, n=10, Fig. 1d ), suggesting that local production may contribute to increased DMV exposure to TNFα.
The Fourth Intracerebral Ventricle TNFα Causes Activation of Microglia
To investigate the effects of TNFα in the DMV, we administered TNFα directly into the fourth intracerebral ventricle (4 V) of healthy adult male rats. As microglia respond to inflammation and participate in local inflammatory responses, we evaluated the activation of microglia by Cd11b immunofluorescence. The 4 V TNFα caused a significant increase in Cd11b immunofluorescence at 24 h after injection (1.5±0.2 vs. 1.0±0.1, n=22, p<0.05; Fig. 2 ). Co-administration of TNFα and SPD304, a small molecule inhibitor to TNFR1, decreased Cd11b immunofluorescence to control values (1.1± 0.1 vs. 1.0±0.1, n=22, p=not significant (NS)). These results indicate that TNFα causes microglial activation via activation of its receptor, TNFR1.
The 4 V TNFα Causes Production of Prothrombin
We previously observed that TNBS colitis is associated with an increase in DMV prothrombin production and hypothesized that TNFα may contribute to elevated prothrombin levels within the DMV. We thus evaluated prothrombin immunofluorescence following the 4 V injection of TNFα (700 pg/dose, two doses). At 24 h post-exposure, there was a mean 27 % increase in prothrombin immunofluorescence in TNFα-treated rats compared to controls (1.3±0.1 vs. 1.0±0.1, n=8, p<0.05; Fig. 3 ). This increase was prevented by TNFR1 blockade via co-administration of SPD304 (TNFα+SPD304 1.1±0.1 vs. control 1.0±0.1, n=8, p=NS; Fig. 3 ), suggesting that TNFα can contribute to elevated prothrombin concentrations within the DMV.
The 4 V TNFα Causes DMV Neuron Apoptosis
To determine whether TNFα is capable of triggering DMV neuronal apoptosis in TNBS colitis, we evaluated TUNEL positivity in Hu-positive DMV neurons following exposure to TNFα via the fourth ventricle. TNFα caused DMV neuron apoptosis at 24 h post-exposure as measured by TUNEL assay (1.31±0.1 vs. 1.0±0.1, n=12, p<0.05; Fig. 4) . Concurrent TNFR1 blockade with SPD304 prevented DMV TNFα-induced neuronal apoptosis (1.1±0.1 vs. control 1.0±0.1, n=12, p=NS; Fig. 4 ). To investigate whether thrombin might Fig. 1 TNFα in IBD. Serum TNFα concentration increased following induction of colitis via TNBS enema (a) (n=10, p=NS, by paired t test) but did not increase following saline enema. Animals with colitis had elevated concentrations of TNFα in CSF (b) (n=9, p=NS, by t test) and DMV tissues (c) (n=10, p=NA). TNFα transcripts were also increased in the DMV tissues of rats with colitis relative to controls (d) (n=8, p=NS, by t test) play a role in TNFα-induced neuronal apoptosis, TNFα was administered in conjunction with the PAR1 antagonist FR171113. PAR1 blockade also prevented TNFα-induced apoptosis (1.1 ± 0.1 vs. control 1.0 ± 0.1, n = 10, p = NS; Fig. 4) , implicating thrombin and its receptor in this process. A similar pattern was observed when examining activated caspase-3 immunofluorescence in DMV neurons (Fig. 5) . TNFα-treated animals had a 52 % increase in activated caspase-3 immunofluorescence as compared to controls; this increase could be blocked by either TNFR1 blockade or PAR1 blockade.
Discussion
Inflammatory bowel disease (IBD) has been associated with dysfunctional regulation of gastrointestinal motility by the autonomic nervous system. As the most significant parasympathetic circuit innervating the GI tract, the vagus nerve is a logical candidate to mediate gastrointestinal dysfunction. Our previous study suggests a mechanism by which IBD may lead to vagal dysfunction: IBD is associated with increased DMV vagal neuron exposure to thrombin; thrombin causes DMV neuronal apoptosis and blunted responses to both excitatory and inhibitory neurotransmitters. In rodents, the 4 V thrombininduced vagal dysfunction results in delayed gastrointestinal transit. 12 While the effects of thrombin on vagal reflexes have been characterized, the cause of excess DMV thrombin in IBD has not been determined.
The present studies identify TNFα as a potential intermediate in the development of thrombin-related DMV neuronal apoptosis in IBD. The following observations support this hypothesis: (1) TNBS colitis was associated with elevated levels of TNFα in rat serum, CSF, and DMV tissues; (2) TNFα delivered via the fourth ventricle caused increased DMV prothrombin levels; (3) TNFα delivered via the fourth ventricle caused DMV neuronal apoptosis with activation of caspase-3; and (4) TNFα-induced DMV neuronal apoptosis could be prevented by blockade of TNFα receptor 1 or the thrombin receptor PAR1. These studies suggest that IBD is associated with elevated TNFα in both the systemic circulation and the central nervous system and that TNFα exposure can cause DMV neuron apoptosis that is sensitive to thrombin receptor blockade.
The relevance of this study is limited by the fidelity of the model utilized. TNBS colitis in rats has been widely used to study IBD because of the similarity of its colonic and constitutional manifestations to human ulcerative colitis. The degree to which it simulates the CNS effects of IBD in humans is less clear. Additionally, while attempts were made to ensure that the doses of TNFα and the receptor antagonists utilized were physiologically relevant, the concentrations of their endogenous counterparts in states of health and disease are not definitively established, particularly within the CNS.
These observations suggest several potential pathways for the development of DMV neuronal apoptosis in IBD. Activation of microglia and neuronal apoptosis are each observed in the DMV after administration of TNFα. While microglial activation may prompt the production of prothrombin and resultant apoptosis, it is also possible that microglial activation is associated with but not causally related to neuronal apoptosis. While our studies have identified two inflammatory mediators involved in DMV neuronal apoptosis in IBD, the roles of the many other inflammatory cytokines involved in IBD are unknown. Several of these cytokines, including IL-1β, are known to cause DMV neuronal apoptosis in vitro; others cytokines such as IL-6 decrease DMV neuronal proliferation. 13 IBD-related autonomic dysfunction may be the net result of the action of many different inflammatory mediators, including thrombin and TNFα, acting on vagovagal circuits.
The role of TNFα in IBD has been studied in detail, resulting in the widespread therapeutic use of anti-TNFα agents. Circulating TNFα concentrations are more than 300-fold higher in patients with IBD than healthy controls and are also higher in active as opposed to quiescent disease.
14 Serum levels of soluble TNF receptors 1 and 2 were similarly elevated in IBD patients, particularly in those patients with active Crohn's disease. 15 Local expression of TNFα by colon tissue is higher in patients with ulcerative colitis than in controls, 1 and elevated TNFR1 and TNFR2 expression has also been reported in rodent models of colitis. 16 Colonic TNFα is implicated in the disruption of intestinal epithelial barrier 17 and impaired wound closure 18 at pathologic concentrations. In addition to its local and systemic effects, there is evidence that TNFα may also affect the central nervous system in IBD. TNFα is readily transported across an intact blood-brain barrier by a saturable transport system. 2 States of CNS inflammation, such as autoimmune encephalitis, are associated with the upregulation of TNFα transport into the CNS. 19 In conditions of systemic inflammation such as sepsis, the blood-brain barrier may be made more permeable by TNFα, but alterations in the transport of TNFα itself have not yet been examined. 20 Increased CNS exposure to TNFα may also result from increased local production. In an intestinal ischemia/reperfusion model of systemic inflammation, for example, TNFα expression was upregulated within the brain. 21 Our studies confirm increased CNS TNFα in IBD, with elevated CSF (TNFα), and indicate several potential mechanisms of augmented exposure. Elevated concentrations of circulating TNFα in IBD suggest the possibility of increased blood-to-brain transport; increased DMV expression of TNFα suggests upregulation of local production. Both mechanisms may play a role.
TNFα has global effects on CNS function in IBD. Rats with TNBS colitis exhibit increased intrinsic neuronal excitability as well as greater propensity for myoclonic seizure activity in response to provocative stimulus. This increase in CNS excitability is dependent upon both TNFα and microglial activations and indicates that IBD-induced elevations in CNS TNFα can affect neuronal function. 22 In addition to its global CNS effects in IBD, TNFα also has specific effects on the discrete neuronal and glial populations involved in vagovagal circuits. The net result is impaired gastrointestinal motility. The vagus nerve forms a reflex arc in which sensory information is transmitted from the GI tract TNFα causes DMV neuron apoptosis. Following exposure to artificial CSF, TNFα, TNFα+the TNFR1 inhibitor SPD304 or TNFα+ the PAR1 inhibitor FR171113 administered via the fourth ventricle, rats were sacrificed at 24 h. Neurons were stained with an antibody against the neuronal marker Hu (a) (green, all images×60 magnification) to identify neurons (indicated by arrow). TUNEL co-staining (b) (red) was then utilized to examine apoptosis in the DMV, and the images merged to confirm localization of TUNEL signal within neurons (c) (merged: TUNEL, Hu, DAPI). TNFα-treated animals had a significant increase in TUNEL signal as compared to controls (n=12, p=0.001), whereas animals treated with either SPD304 or FR171113 in addition to TNFα exhibited no significant difference in TUNEL signal compared to controls (n=12 and n=10, respectively, p=NS for each by Bonferroni test) to the nucleus of the solitary tract (NTS) in the brain stem. NTS neurons synapse on efferent vagal motor neurons in the adjacent DMV, which then project back to the GI tract to regulate its function. Injection of TNFα directly into this area of the brain stem results in the activation of a subpopulation of NTS neurons and suppression of DMV-mediated gastric tone. [23] [24] [25] These effects can also be elicited by LPS-induced systemic inflammation and inhibited by intracranial TNFα-adsorbing agents. 25 Our studies demonstrate additional effects of TNFα in the DMV-microglial activation, production of prothrombin, and vagal neuronal apoptosis-all of which may further contribute to autonomic dysfunction in IBD.
Systemic anti-TNFα therapies have proven efficacy in induction of remission for Crohn's disease 26 and ulcerative colitis 27 as well as maintenance of remission in Crohn's disease. 28 Treatment is associated with symptomatic and histological improvement as well as decreased need for operation. 27 Whether anti-TNFα agents or PAR1 blockade may be effective in treating autonomic dysfunction associated with IBD is uncertain. While our studies address the prevention of TNFα-induced DMV neuron apoptosis by TNFR1 and PAR1 blockade, they are not designed to evaluate a potential therapeutic effect in acute TNFα exposure or in IBD.
The main anti-TNFα agents currently in clinical use do not readily enter the CNS. 29 Recently, TNFα inhibitors capable of traversing the blood-brain barrier have been engineered for use in treating neuroinflammatory conditions; these have not been tested in IBD. 30 In contrast, thalidomide is a small molecule inhibitor of TNFα production that readily traverses the blood-brain barrier. In several small series, thalidomide has proven effective in decreasing intestinal inflammation and patient symptoms associated with IBD, even in patients refractory to conventional anti-TNFα therapy. [31] [32] [33] These observations raise the question as to whether thalidomide may affect the pathophysiology of IBD within the CNS as well as peripherally.
Although IBD was originally believed to be a process limited to the gastrointestinal tract, the systemic nature of this disease has long been apparent. Still, the effects of IBD on the central nervous system and the contributions of CNS dysfunction to the pathophysiology of IBD have only recently been investigated. These studies indicate that IBD is associated with increased brain stem exposure to TNFα, resulting in activation of microglia, production of prothrombin, and apoptosis in vagal neurons. This may be one mechanism by which autonomic dysfunction develops in patients with IBD and may represent a potential target for therapeutic intervention.
